Indica
Backed by cutting edge technology, an uncompromising focus on ease-of-use and dedicated customer service, Indica Labs’ software and services are being used to make vital discoveries in pathology labs and research organizations around the world.

Spatial Organization of Immune Cells in the Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment

Indica Labs / Events  / Spatial Organization of Immune Cells in the Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment

Spatial Organization of Immune Cells in the Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment

In lieu of our participation in the now cancelled 2020 AACR Conference, Indica Labs are pleased to bring you webinar presentations from two of our esteemed customers in oncology research and drug discovery, David Krull from GlaxoSmithKline and Dr. David Reiss from Bristol Meyers Squibb, who will present on April 27th and 28th, respectively. Please join us to hear about how Indica Labs image analysis software and pharma services are being used within their organizations to advance oncology drug development.

PLEASE NOTE you will need to register separately for each webinar presentation if you wish to attend both events.  Webinar recordings will be sent to all registered delegates at the conclusion of the webinar series.

Available On-Demand

28 April, 2020
8:00 PDT | 11:00 EDT | 16:00 BST

Spatial Organization of Immune Cells in the Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment

It is difficult to develop successful treatments for PDAC; even with curative resection, most patients die from early occult metastases. Immune checkpoint therapy has so far been unsuccessful at improving patient outcomes. Prior studies identified the presence of tumor-infiltrating lymphocytes (TILs) in primary PDAC tumors as having prognostic significance in the PDAC adjuvant setting. The phase 3 APACT trial evaluated the use of adjuvant nab-paclitaxel plus gemcitabine vs. gemcitabine in 866 patients with PDAC who had undergone primary tumor resection, with the primary endpoint of disease-free survival evaluated by independent review. We extended studies of the tumor microenvironment of PDAC to a large set of resected APACT primary tumors in an effort to further refine features of tumor or immune infiltrate that influence disease progression and to determine if chemotherapy regimen–specific predictive signatures are identifiable. In this webinar, we will describe the methods and preliminary analytics obtained from this study which provide an unprecedented opportunity for exploratory analysis and discovery of immune, molecular, and genetic biomarkers for PDAC patient stratification.

Dr. David Reiss, PhD
Sr. Scientist, Translational Informatics & Predictive Sciences, Bristol Meyers Squibb

Dr. Reiss develops methods for statistical analysis and modeling, machine learning, and visualization to gain novel insights from large and complex data sets. Dr. Reiss holds a doctorate degree in Astrophysics from the University of Washington and has worked in diverse areas of research, including astrophysics, microbial systems biology, and currently oncology and digital pathology.